Chemomab
Barbara Lindheim has provided strategic communications services to the biotechnology and life sciences industries for more than 25 years. Her industry experience spans public relations, strategic positioning, corporate and product communications, crisis management and social media. Her experience in investor relations includes financings, IPOs and investor outreach. Ms. Lindheim is a principal at BLL Partners, LLC and previously held senior communications and strategy roles at Lodo Therapeutics, Orchid BioSciences, Edelman Public Relations, BioCom Partners, Noonan Russo Communications, Glaxo SmithKline, Pfizer and Sanofi. Earlier in her career, Ms. Lindheim developed public policy and advocacy programs for non-profit and government organizations. An Honors graduate of Cornell University, Ms. Lindheim earned an MBA with distinction from Harvard Business School and a master’s degree in public policy from Princeton University.
This person is not in any teams
This person is not in any offices
Chemomab
Chemomab Therapeutics (NASDAQ: CMMB), is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases.